Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
08 06 2023
Historique:
medline: 9 6 2023
pubmed: 30 5 2023
entrez: 29 5 2023
Statut: ppublish

Résumé

Prolyl oligopeptidase (PREP) is a widely distributed serine protease in the human body cleaving proline-containing peptides; however, recent studies suggest that its effects on pathogenic processes underlying neurodegeneration are derived from direct protein-protein interactions (PPIs) and not from its regulation of certain neuropeptide levels. We discovered novel nonpeptidic oxazole-based PREP inhibitors, which deviate from the known structure-activity relationship for PREP inhibitors. These new compounds are effective modulators of the PPIs of PREP, reducing α-synuclein (αSyn) dimerization and enhancing protein phosphatase 2A activity in a concentration-response manner, as well as reducing reactive oxygen species production. From the best performing oxazoles,

Identifiants

pubmed: 37248563
doi: 10.1021/acs.jmedchem.3c00235
pmc: PMC10258805
doi:

Substances chimiques

alpha-Synuclein 0
Ligands 0
Prolyl Oligopeptidases EC 3.4.21.26
Serine Endopeptidases EC 3.4.21.-
Oxazoles 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7475-7496

Références

Peptides. 2008 Sep;29(9):1472-8
pubmed: 18571285
Sci Rep. 2018 Jan 24;8(1):1552
pubmed: 29367610
Mol Neurobiol. 2018 Jan;55(1):470-482
pubmed: 27966077
Basic Clin Pharmacol Toxicol. 2014 Jun;114(6):460-3
pubmed: 24350801
Biomed Pharmacother. 2020 Nov;131:110788
pubmed: 33152946
Biomed Pharmacother. 2022 Feb;146:112501
pubmed: 34891119
Neurosci Lett. 2017 Jan 1;636:83-89
pubmed: 27818354
Front Mol Neurosci. 2014 Mar 11;7:16
pubmed: 24653673
J Neurosci. 2011 May 11;31(19):6963-71
pubmed: 21562258
Neurosci Lett. 2004 Aug 26;367(1):34-9
pubmed: 15308292
J Biol Chem. 2015 Feb 20;290(8):5117-5126
pubmed: 25555914
Free Radic Biol Med. 2021 Jun;169:14-23
pubmed: 33838285
Protein Eng Des Sel. 2017 Mar 1;30(3):217-224
pubmed: 28062644
Agric Biol Chem. 1991 Jan;55(1):37-43
pubmed: 1368673
J Neurosci Res. 2019 Mar;97(3):346-361
pubmed: 30548446
J Clin Pharmacol. 1999 May;39(5):462-70
pubmed: 10234593
Mol Cell Neurosci. 2009 Jul;41(3):373-82
pubmed: 19332125
Bioorg Med Chem Lett. 2007 Sep 1;17(17):4733-6
pubmed: 17644333
CNS Drug Rev. 2002 Spring;8(1):31-52
pubmed: 12070525
J Neurochem. 2004 Oct;91(2):451-61
pubmed: 15447678
Neurosci Lett. 2008 Apr 11;435(1):24-9
pubmed: 18314273
ACS Med Chem Lett. 2021 Sep 17;12(10):1578-1584
pubmed: 34671446
Br J Pharmacol. 2012 Jun;166(3):1097-113
pubmed: 22233220
ACS Med Chem Lett. 2019 Nov 11;10(12):1635-1640
pubmed: 31857839
J Biol Chem. 1998 Feb 13;273(7):3963-6
pubmed: 9461583
J Neurosci. 2016 Dec 7;36(49):12485-12497
pubmed: 27927963
Neurobiol Dis. 2014 Aug;68:1-15
pubmed: 24746855
Pharmacol Res. 2020 Jan;151:104558
pubmed: 31759088
Biochem Pharmacol. 2019 Mar;161:113-120
pubmed: 30660495
J Med Chem. 2004 Nov 4;47(23):5605-7
pubmed: 15509157
Neurosci Lett. 2014 Nov 7;583:37-42
pubmed: 25240592
Neuropharmacology. 2022 Nov 1;218:109213
pubmed: 35964686
Sci Rep. 2019 Nov 22;9(1):17382
pubmed: 31758049
PLoS One. 2014 Mar 11;9(3):e90857
pubmed: 24618582
J Mol Neurosci. 2015 Jan;55(1):99-108
pubmed: 25069858
Sci Transl Med. 2023 Apr 12;15(691):eabq2915
pubmed: 37043557
Br J Clin Pharmacol. 1997 Jun;43(6):613-8
pubmed: 9205821
Neurobiol Dis. 2006 Feb;21(2):431-43
pubmed: 16230020
Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):443-51
pubmed: 21707925
J Biol Chem. 1976 Dec 10;251(23):7593-9
pubmed: 12173
Biomed Pharmacother. 2020 Aug;128:110253
pubmed: 32447211
Neurosci Lett. 1992 Jul 20;141(2):156-60
pubmed: 1436628
Biochem Pharmacol. 2006 Feb 28;71(5):683-92
pubmed: 16405869
J Mol Biol. 2004 Jul 9;340(3):627-37
pubmed: 15210359
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2884-9
pubmed: 12601150
Eur J Neurosci. 2018 Sep;48(6):2354-2361
pubmed: 30144349
Mol Cell. 2016 Nov 17;64(4):835-849
pubmed: 27818143
Angew Chem Int Ed Engl. 2012 Nov 5;51(45):11367-70
pubmed: 23047285
Brain. 2023 Apr 19;146(4):1496-1510
pubmed: 36073231
J Med Chem. 2010 May 13;53(9):3423-38
pubmed: 20058865
Genes (Basel). 2017 Feb 08;8(2):
pubmed: 28208742
Org Lett. 2010 Feb 19;12(4):820-3
pubmed: 20088495
Sci Rep. 2017 May 26;7(1):2456
pubmed: 28550305
Neuropeptides. 2007 Feb;41(1):1-24
pubmed: 17196652
J Med Chem. 2012 Nov 26;55(22):9856-67
pubmed: 23121075

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH